Leuven dose-dense paclitaxel/carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma

International Journal of Gynecological Cancer

Volumn 19, Issue 6, 2009, Pages 1147-1151

  Vandenput, Ingrid ^a   Vergote, Ignace ^a   Leunen, Karin ^a   Berteloot, Patrick ^a   Neven, Patrick ^a   Amant, Frédéric ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Advanced disease; Dose dense regimen; Endometrial cancer; Paclitaxel carboplatin; Recurrence

Indexed keywords

CARBOPLATIN; CETIRIZINE; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; IRON; ONDANSETRON; PACLITAXEL; PROMETHAZINE; RANITIDINE; TOPOTECAN; TROPISETRON;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IRON THERAPY; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; DISEASE PROGRESSION; DOSAGE FORMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 70349263385     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181ad3dcb     Document Type: Article

References (23)

1. Sankaranarayana R.Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2006;20:207-225.
2. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet. 2005;366:591-605.
3. Tropé C, Alektiar K, Sabbatini P, et al. Corpus: epithelial tumors. In: Hoskins W, Perez C, eds. Principles and Practice of Gynecologic Oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005:856.
4. Hoskins P, Swenerton K, Pike J, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol. 2001;19:4048-4053.
5. van Der Burg M, van Der Gaast A, Vergote I, et al. What is the role of dose-dense therapy? Int J Gynecol Cancer. 2005;15:233-240.
6. Cadron I, Leunen K, Amant F, et al. The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer. Gynecol Oncol. 2007;106:354-361. (Pubitemid 47087932)
7. Isonishi S, Yasuda M, Takahashi F, et al. Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology. J Clin Oncol. 2008;26:abstr 5506.
8. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92:205-216. (Pubitemid 30099779)
9. Barrett R, Blessing J, Homesley H, et al. Circadian-timed combination doxorubicin cisplatin chemotherapy for advanced endometrial carcinoma: a phase II study of the Gynecologic Oncology Group. Am J Clin Oncol. 1993;16:494-496. (Pubitemid 24004100)
10. Tropé C, Johnsson J, Simonsen E, et al. Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin. Am J Obstet Gynecol. 1984;149:379-381.
11. Long H, Pfeifle D, Wiand H, et al. Phase II evaluation of carboplatin in advanced endometrial carcinoma. J Natl Cancer Inst. 1988;80:276-278.
12. Burke T, Munkarah A, Kavanagh J, et al. Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol Oncol. 1993;51:397-400.
13. Aapro M, van Wijk F, Bolis G, et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definite results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol. 2003;14:441-448.
14. Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004;22:3902-3908.
15. Sovak M, Dupont J, Hensley M, et al. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int J Gynaecol Cancer. 2007;17:197-203.
16. Arimoto T, Nakagawa S, Yasugi T, et al. Treatment with paclitaxel plus carboplatin, alone or with irradiation, of advanced or recurrent endometrial cancer. Gynecol Oncol. 2007;104:3235.
17. Sorbe B, Andersson H, Boman K, et al. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int J Gynecol Cancer. 2008;18:803-808.
18. Pectasides D, Xiros N, Papaxonis G, et al. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol. 2008;109:250-254.
19. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22:2159-2166. (Pubitemid 41095150)
20. Fleming G, Filiaci V, Bentley R, et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol. 2004;15:1173-1178. (Pubitemid 39199303)
21. Günthert A, Ackermann S, Beckmann M, et al. Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4. Gynecol Oncol. 2007;104:86-90.
22. Dimopoulos M, Papadimitriou C, Georgoulias V, et al. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Gynecol Oncol. 2000;78:52-57. (Pubitemid 30439479)
23. Papadimitriou C, Bafaloukos D, Bozas G, et al. Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. Gynecol Oncol. 2008;110:87-92.